329 related articles for article (PubMed ID: 10402467)
1. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner.
Nguyen DH; Catling AD; Webb DJ; Sankovic M; Walker LA; Somlyo AV; Weber MJ; Gonias SL
J Cell Biol; 1999 Jul; 146(1):149-64. PubMed ID: 10402467
[TBL] [Abstract][Full Text] [Related]
2. Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion.
Webb DJ; Nguyen DH; Gonias SL
J Cell Sci; 2000 Jan; 113 ( Pt 1)():123-34. PubMed ID: 10591631
[TBL] [Abstract][Full Text] [Related]
3. Cooperativity between the Ras-ERK and Rho-Rho kinase pathways in urokinase-type plasminogen activator-stimulated cell migration.
Jo M; Thomas KS; Somlyo AV; Somlyo AP; Gonias SL
J Biol Chem; 2002 Apr; 277(14):12479-85. PubMed ID: 11805108
[TBL] [Abstract][Full Text] [Related]
4. Urokinase-type plasminogen activator stimulates the Ras/Extracellular signal-regulated kinase (ERK) signaling pathway and MCF-7 cell migration by a mechanism that requires focal adhesion kinase, Src, and Shc. Rapid dissociation of GRB2/Sps-Shc complex is associated with the transient phosphorylation of ERK in urokinase-treated cells.
Nguyen DH; Webb DJ; Catling AD; Song Q; Dhakephalkar A; Weber MJ; Ravichandran KS; Gonias SL
J Biol Chem; 2000 Jun; 275(25):19382-8. PubMed ID: 10777511
[TBL] [Abstract][Full Text] [Related]
5. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility.
Nguyen DH; Hussaini IM; Gonias SL
J Biol Chem; 1998 Apr; 273(14):8502-7. PubMed ID: 9525964
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth.
Webb DJ; Thomas KS; Gonias SL
J Cell Biol; 2001 Feb; 152(4):741-52. PubMed ID: 11266465
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
Nicholl SM; Roztocil E; Davies MG
J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
9. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells.
Tang H; Kerins DM; Hao Q; Inagami T; Vaughan DE
J Biol Chem; 1998 Jul; 273(29):18268-72. PubMed ID: 9660790
[TBL] [Abstract][Full Text] [Related]
10. Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade.
Lengyel E; Wang H; Gum R; Simon C; Wang Y; Boyd D
Oncogene; 1997 May; 14(21):2563-73. PubMed ID: 9191056
[TBL] [Abstract][Full Text] [Related]
11. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration.
Yebra M; Parry GC; Strömblad S; Mackman N; Rosenberg S; Mueller BM; Cheresh DA
J Biol Chem; 1996 Nov; 271(46):29393-9. PubMed ID: 8910604
[TBL] [Abstract][Full Text] [Related]
12. Urinary-type plasminogen activator (uPA) expression and uPA receptor localization are regulated by alpha 3beta 1 integrin in oral keratinocytes.
Ghosh S; Brown R; Jones JC; Ellerbroek SM; Stack MS
J Biol Chem; 2000 Aug; 275(31):23869-76. PubMed ID: 10791952
[TBL] [Abstract][Full Text] [Related]
13. Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells.
Ma Z; Webb DJ; Jo M; Gonias SL
J Cell Sci; 2001 Sep; 114(Pt 18):3387-96. PubMed ID: 11591826
[TBL] [Abstract][Full Text] [Related]
14. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling.
Aguirre Ghiso JA; Kovalski K; Ossowski L
J Cell Biol; 1999 Oct; 147(1):89-104. PubMed ID: 10508858
[TBL] [Abstract][Full Text] [Related]
15. An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration.
Mazzieri R; D'Alessio S; Kenmoe RK; Ossowski L; Blasi F
Mol Biol Cell; 2006 Jan; 17(1):367-78. PubMed ID: 16267271
[TBL] [Abstract][Full Text] [Related]
16. Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator.
Jo M; Thomas KS; Marozkina N; Amin TJ; Silva CM; Parsons SJ; Gonias SL
J Biol Chem; 2005 Apr; 280(17):17449-57. PubMed ID: 15728176
[TBL] [Abstract][Full Text] [Related]
17. Rac1-MKK3-p38-MAPKAPK2 pathway promotes urokinase plasminogen activator mRNA stability in invasive breast cancer cells.
Han Q; Leng J; Bian D; Mahanivong C; Carpenter KA; Pan ZK; Han J; Huang S
J Biol Chem; 2002 Dec; 277(50):48379-85. PubMed ID: 12377770
[TBL] [Abstract][Full Text] [Related]
18. Phosphatidylinositol 3-kinase is required for integrin-stimulated AKT and Raf-1/mitogen-activated protein kinase pathway activation.
King WG; Mattaliano MD; Chan TO; Tsichlis PN; Brugge JS
Mol Cell Biol; 1997 Aug; 17(8):4406-18. PubMed ID: 9234699
[TBL] [Abstract][Full Text] [Related]
19. Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase.
Chang AW; Kuo A; Barnathan ES; Okada SS
Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1855-60. PubMed ID: 9848876
[TBL] [Abstract][Full Text] [Related]
20. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
